Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
2.700
+0.120 (4.65%)
At close: Aug 13, 2025, 4:00 PM
2.848
+0.148 (5.47%)
Pre-market: Aug 14, 2025, 8:36 AM EDT
Savara Employees
Savara had 59 employees as of December 31, 2024. The number of employees increased by 22 or 59.46% compared to the previous year.
Employees
59
Change (1Y)
22
Growth (1Y)
59.46%
Revenue / Employee
n/a
Profits / Employee
-$1,870,034
Market Cap
568.86M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SVRA News
- 1 day ago - Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update - Business Wire
- 26 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 2 months ago - Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation - Accesswire
- 2 months ago - Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday? - Benzinga
- 2 months ago - BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses - GlobeNewsWire
- 2 months ago - Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) - Business Wire
- 3 months ago - Savara Announces Participation in Jefferies Global Healthcare Conference - Business Wire
- 3 months ago - Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 - Business Wire